Bristol-Myers Squibb Company

AI Summary

Bristol-Myers Squibb discovers, develops, manufactures, and sells prescription medicines worldwide, focusing on cancer treatments (Opdivo, Yervoy, Breyanzi), immune system drugs (Orencia, Zeposia), blood disorder treatments (Reblozyl, Revlimid), and cardiovascular medicines (Eliquis) [Yahoo Finance]. The company sells through wholesalers, specialty pharmacies, hospitals, and government agencies across global markets [Yahoo Finance].

Bristol-Myers Squibb is a large pharmaceutical company that develops and sells drugs for cancer, immune diseases, heart conditions, and neurological disorders [Yahoo Finance]. The company generates $48.2B in annual revenue, maintains a $119B market cap, and is financially healthy with strong cash flow [Yahoo Finance]. Recent news highlights aggressive AI partnerships with Anthropic and Tempus AI to accelerate drug discovery, plus a major $1B manufacturing expansion in Houston [Yahoo Finance].

Bristol-Myers Squibb is financially healthy with strong profitability and solid cash generation, though revenue is flat year-over-year [Yahoo Finance].

Recent News

• Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

  Yahoo Finance· 2026-05-20

• How The Bristol Myers Squibb (BMY) Story Is Shifting Around Pipeline Hopes And Patent Risks

  Simply Wall St· 2026-05-19

• Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

  Yahoo Finance· 2026-05-20

• Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts

  Benzinga· 2026-05-18

• Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

  Zacks· 2026-05-19

• Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist

  Simply Wall St· 2026-05-18